Ridgetech (RDGT)
NASDAQ:RDGT
Want to see RDGT full AI Analyst Report?
Top Page
Ridgetech
(NASDAQ:RDGT)
Select Model
Select Model
Rating:40Underperform
Price Target:
$2.00
▼(-24.81% Downside)
Action:DowngradedDate:04/24/26
The score is weighed down primarily by weak financial performance (operating losses, recent revenue decline, and historically inconsistent cash flow) despite some 2025 stabilization from positive net income, improved cash flow, and reduced debt. Technicals further pressure the score due to a bearish trend (negative MACD and price below major moving averages), while valuation provides limited support given a negative P/E and no dividend yield data.
Positive Factors
Balance Sheet Improvement
Material debt reduction and higher equity in 2025 reduce near-term solvency risk and provide a larger capital cushion. For a low-margin distributor, lower debt materially increases flexibility to invest in operations or absorb shocks, improving the firm's ability to execute strategic fixes over months.
Negative Factors
Revenue Volatility and Decline
Sustained or recurring revenue declines and volatility undermine operating leverage and planning for a distributor. Weak top-line trends constrain margin recovery, increase unit-cost pressure, and make multi-quarter forecasting and inventory management harder, raising the risk of recurring earnings weakness.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Improvement
Material debt reduction and higher equity in 2025 reduce near-term solvency risk and provide a larger capital cushion. For a low-margin distributor, lower debt materially increases flexibility to invest in operations or absorb shocks, improving the firm's ability to execute strategic fixes over months.
Read all positive factors
Ridgetech (RDGT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.65M
Dividend YieldN/A
Average Volume (3M)35.98K
Price to Earnings (P/E)―
Beta (1Y)-0.30
Revenue Growth-24.14%
EPS Growth75.39%
CountryUS
Employees939
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding898,918
10 Day Avg. Volume73,880
30 Day Avg. Volume35,985
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00032
P/FCF Ratio0.06
Enterprise Value/Market Cap-5.61
Enterprise Value/Revenue-0.08
Enterprise Value/Gross Profit1.12
Enterprise Value/Ebitda-1.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ridgetech Business Overview & Revenue Model
Company Description
Ridgetech Inc operates as a holding company. The Company, through its subsidiaries, wholesales, distributes, and retails pharmaceutical and other healthcare products....
Ridgetech Financial Statement Overview
Summary
Income Statement
41
Neutral
Balance Sheet
38
Negative
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 111.62M | 119.97M | 154.54M | 148.81M | 164.39M | 133.13M |
| Gross Profit | -8.29M | 3.84M | 31.11M | 34.28M | 36.52M | 29.24M |
| EBITDA | 6.66M | 4.98M | 1.23M | -19.96M | -579.93K | -6.14M |
| Net Income | 12.41M | 10.19M | -4.23M | -21.14M | -3.19M | -8.12M |
Balance Sheet | ||||||
| Total Assets | 61.39M | 64.48M | 95.06M | 90.97M | 106.38M | 106.31M |
| Cash, Cash Equivalents and Short-Term Investments | 13.94M | 12.78M | 20.15M | 18.81M | 18.46M | 22.14M |
| Total Debt | 4.66M | 10.39M | 43.22M | 42.16M | 48.67M | 46.78M |
| Total Liabilities | 31.61M | 34.85M | 80.76M | 74.30M | 83.65M | 81.91M |
| Stockholders Equity | 29.78M | 29.64M | 15.64M | 18.01M | 24.09M | 25.74M |
Cash Flow | ||||||
| Free Cash Flow | 5.35M | 632.50K | -4.08M | -3.60M | -5.69M | -666.47K |
| Operating Cash Flow | 5.35M | 1.25M | -3.16M | -3.28M | -5.39M | -62.29K |
| Investing Cash Flow | 0.00 | -18.14M | -2.04M | -316.10K | -306.14K | -2.00M |
| Financing Cash Flow | -5.87M | 1.51M | 8.00M | 2.37M | 4.84M | 3.08M |
Ridgetech Technical Analysis
Negative
2.66
Price Trends
178.71
Negative
323.65
Negative
281.65
Negative
Market Momentum
-61.72
Negative
32.70
Neutral
4.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDGT, the sentiment is Negative. The current price of 2.66 is below the 20-day moving average (MA) of 54.54, below the 50-day MA of 178.71, and below the 200-day MA of 281.65, indicating a bearish trend. The MACD of -61.72 indicates Negative momentum. The RSI at 32.70 is Neutral, neither overbought nor oversold. The STOCH value of 4.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RDGT.
Ridgetech Risk Analysis
Ridgetech disclosed 58 risk factors in its most recent earnings report. Ridgetech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
HJ Group is subject to restrictions on making payments to us. Q1, 2023
Ridgetech Peers Comparison
UnderperformOutperform
Sector (51)
RDGT
Ridgetech
1.75
-137.93
-98.75%
GEG
Great Elm Group
2.06
0.12
6.19%
SNYR
Synergy CHC
0.39
-1.53
-79.79%
WGRX
Wellgistics Health Inc
0.12
-3.82
-96.85%
Ridgetech Corporate Events
Ridgetech Completes 1-for-150 Reverse Share Split and Updates Capital Structure
Apr 10, 2026
Ridgetech, Inc. disclosed that its board-approved 1-for-150 reverse share split of ordinary shares, authorized by shareholders at the December 12, 2025 annual meeting, became effective at 5:00 p.m. Eastern Time on April 7, 2026. The move consolida...
Ridgetech Announces 1-for-150 Reverse Share Split to Take Effect April 7, 2026
Apr 3, 2026
Ridgetech, Inc., a wholesale distributor of pharmaceutical and healthcare products in China listed on Nasdaq under the ticker RDGT, announced on April 3, 2026 that it will execute a 1-for-150 reverse share split of its ordinary shares. The move wi...
Ridgetech Posts Flat Half-Year Revenue but Slightly Stronger Balance Sheet
Mar 5, 2026
Ridgetech, Inc. has furnished its unaudited interim financial results for the six months ended Sept. 30, 2025, reporting essentially flat revenue of $62.8 million compared with the same period in 2024 and a slight increase in gross profit to $2.46...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.